newsfilter
← Latest News
GlobeNewswire·

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

GLSI
  • Greenwich LifeSciences (NASDAQ: GLSI) announced its abstract on FLAMINGO-01 trial data will be presented at the 2026 ASCO Annual Meeting from May 28 to June 2, 2026.
  • Full text of the abstract & poster will be available on June 1, 2026, featuring preliminary injection site reaction immune response data from the non-HLA-A*02 open-label arm.
  • The non-HLA-A*02 arm of FLAMINGO-01 is fully enrolled with 250 patients, representing 5 times more treated patients than the Phase IIb trial.
  • Preliminary analysis shows an approximately 70-80% reduction in breast cancer recurrence rates after the Primary Immunization Series (PIS) in the non-HLA-A*02 population.
  • Delayed-type-hypersensitivity (DTH) reactions in the non-HLA-A*02 population increased by approximately 4x (290%), rising from 5.2% at baseline to 20.4% by month 4 or 6.
  • HLA-A types exhibited more frequent immune reactivity after GLSI-100 treatment, with frequencies increasing from 100% to 700% compared to baseline.
  • Phase IIb trial results demonstrated an 80% or greater reduction in metastatic breast cancer recurrence over 5 years for HER2/neu 3+ patients treated with GLSI-100.
  • FLAMINGO-01 is a Phase III trial evaluating Fast Track designated GLSI-100 in HER2 positive breast cancer patients with residual disease or high-risk pathologic complete response.
  • The trial aims to enroll up to 500 HLA-A*02 patients in double-blinded arms & up to 250 patients of other HLA types in a third open-label arm.
  • Greenwich LifeSciences plans to attend ESMO Breast, BIO partnering, & investor conferences in the coming months.